Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Anthony Scarsella

Family Medicine Beverly Hills, CA Medical Doctor

NPI 1902901010 CMS profile 132183

150 N Robertson Blvd, #300, Beverly Hills, CA 90211

Open in the dashboard

General payments

$9,829

502 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,425,498 paid to institutions, not to them · program years 2019–2024

Through program year 2024, Anthony Scarsella of Beverly Hills, CA is reported in the CMS Open Payments database as having received $9,829 across 502 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,425,498 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $20 1
2022 General $682 29
2021 General $3,033 166
2020 General $3,484 135
2019 General $2,611 171

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Scarsella
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Anthony Scarsella were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Anthony Scarsella Family Medicine median Middle half National median
2019 $2,611 $150 $41–$543 $163
2020 $3,484 $120 $32–$415 $114
2021 $3,033 $137 $35–$551 $132
2022 $682 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $20 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Gilead Sciences, Inc. $1,963 105 payments
  2. Merck Sharp & Dohme Corporation $1,664 28 payments
  3. ViiV Healthcare Company $1,352 96 payments
  4. EMD Serono, Inc. $796 46 payments
  5. Novo Nordisk Inc $646 41 payments
  6. Napo Pharmaceuticals Inc $516 37 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $441 22 payments
  8. Janssen Biotech, Inc. $345 21 payments
  9. Amgen Inc. $264 11 payments
  10. AbbVie, Inc. $246 11 payments
  11. Other $1,596 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $8,445 473 payments
  2. Travel and Lodging $927 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $376 25 payments
  4. Education $81 2 payments
Products named General payments · program years 2019–2024
  1. MK-8591A $1,263 7 payments
  2. DOVATO $1,103 81 payments
  3. Mytesi $516 37 payments
  4. SYMTUZA $341 20 payments
  5. PIFELTRO $280 14 payments
  6. ISENTRESS $280 14 payments
  7. DELSTRIGO $280 14 payments
  8. TRINTELLIX $280 13 payments
  9. SEROSTIM $269 20 payments
  10. Saxenda $236 15 payments
  11. Other $4,411 235 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

502 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record